Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study.

Maud ToulmondeJean-Yves BlayOlivier BoucheOlivier MirNicolas PenelNicolas IsambertFlorence DuffaudEmmanuelle BompasThomas EsnaudRomain BoidotDamien GenesteFrançois GhiringhelliCarlo LucchesiCarine A BelleraFrançois Le LoarerAntoine Italiano

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Palbociclib has no significant clinical activity as a single agent in P16/CDKN2A -deleted GIST refractory to imatinib and sunitinib.

Keyphrases

phase ii study
renal cell carcinoma
metastatic renal cell carcinoma
chronic myeloid leukemia
open label
locally advanced
metastatic breast cancer
squamous cell carcinoma
radiation therapy
placebo controlled
double blind